GID Bio
CO - LouisvilleBiotechnology
Focus: GID Bio is a cell therapy biotech focused on stromal vascular fraction (SVF) cell treatments spanning oncology, gene therapy, and regenerative medicine applications. The company operates as a pre-revenue stage biotech with a diversified pipeline addressing unmet needs in musculoskeletal, neurological, and metabolic diseases.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About GID Bio
AI assessmentNot HiringNo open roles listed right now. Follow GID Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
GID SVF-2
Erectile DysfunctionClinical Trials (1)
NCT03886402Adipose-derived SVF for Treatment of Erectile Dysfunction (ED)
N/AHelp build intelligence for GID Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.